References Nature Communications Biology FOXO4-DRI induces keloid senescent fibroblast apoptosis by promoting nuclear exclusion of upregulated p53-serine 15 phosphorylation Nature Cell Targeted apoptosis of senescent cells restores tissue homeostasis in response to chemotoxicity and aging (original FOXO4-DRI discovery) Aging (Albany NY) FOXO4-DRI alleviates age-related testosterone secretion insufficiency by targeting senescent Leydig cells in aged mice Journal of Cellular and Molecular Medicine FOXO4 peptide targets myofibroblast ameliorates bleomycin-induced pulmonary fibrosis in mice Cell Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice (senolytic mechanism context) Aging (Albany NY) Methods & Protocols FOXO4-DRI safety note: no human clinical dosing data exist yet PubMed A liquid chromatography high-resolution mass spectrometry in vitro assay to assess metabolism at the injection site of subcutaneously administered therapeutic peptides Bachem Care and Handling of Peptides (storage, reconstitution, stability guidance) MedlinePlus Subcutaneous (SQ) injections: technique, site selection, and safety American Diabetes Association Insulin injection site rotation and lipohypertrophy prevention CDC Vaccine administration: subcutaneous route (angle, site
doi: 10.1016/j.foodchem.2009.03.014 60
Compounded products from licensed 503A pharmacies follow USP standards for sterility and potency, and provider evaluation is a routine part of legitimate access to any compounded injection
A cornerstone of Bryan Johnsons protocol
The Bottom Line The FDA must still decide whether to adopt the Pharmacy Compounding Advisory Committees recommendation to add BPC-157 to the 503A Bulks List
doi:10.1038/nature02317 Onoue S, Tsuda Y (2006) Analytical studies on the prediction of photosensitive/phototoxic potential of pharmaceutical substances
_1772706284.jpg)
